On May 16, 2019 Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, reported the presentation of updated clinical data for its potent and highly selective investigational medicines avapritinib and BLU-667 (Press release, Blueprint Medicines, MAY 16, 2019, View Source [SID1234536441]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
At the 2019 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting and 24th Congress of the European Hematology Association (EHA) (Free EHA Whitepaper), Blueprint Medicines plans to present:
Data from the expansion portion of the registration-enabling ARROW trial of BLU-667 in patients with RET-altered non-small cell lung cancer (NSCLC) and thyroid cancers
Data from the registration-enabling NAVIGATOR trial of avapritinib in patients with PDGFRA Exon 18 mutant and fourth-line gastrointestinal stromal tumors (GIST), which will be used for planned marketing applications in the United States and Europe
Data from the registration-enabling EXPLORER trial of avapritinib in patients with advanced systemic mastocytosis (SM)
"Our upcoming presentations highlight data supporting our plans for multiple marketing applications in the United States and Europe over the next 18 months and demonstrate continued progress on our ‘2020 Blueprint’ strategy," said Andy Boral, M.D., Ph.D., Chief Medical Officer of Blueprint Medicines. "The datasets reflect the rapid development of avapritinib and BLU-667, including in four indications that have received Breakthrough Therapy Designation from the FDA. These presentations for avapritinib and BLU-667 highlight the breadth and speed of development of our portfolio, as well as our commitment to rapidly deliver new precision therapies to cancer patients with limited or no effective treatment options."
The accepted abstracts are listed below and are now available online on the ASCO (Free ASCO Whitepaper) and EHA (Free EHA Whitepaper) conference websites, respectively: View Source and View Source
2019 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting
May 31-June 4, 2019; Chicago, Illinois
Oral Presentation
Presentation Title: Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC)
Session Title: Lung Cancer—Non-Small Cell Metastatic
Session Date & Time: Monday, June 3, 2019 from 8:00 a.m. – 11:00 a.m. CT (9:00 a.m. – 12:00 p.m. ET)
Abstract Number: 9008
Poster Discussion Presentations
Presentation Title: Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers
Session Title: Head and Neck Cancer
Poster Session Date & Time: Saturday, June 1, 2019 from 1:15 p.m. – 4:15 p.m. CT (2:15 p.m. – 5:15 p.m. ET)
Poster Discussion Session Date & Time: Saturday, June 1, 2019 from 4:30 – 6:00 p.m. CT (5:30 p.m. – 7:00 p.m. ET)
Abstract Number: 6018
Presentation Title: Clinical activity of avapritinib in ≥ fourth line (4L+) and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST)
Session Title: Sarcoma
Poster Session Date & Time: Saturday, June 1, 2019 from 8:00 a.m. – 11:00 a.m. CT (9:00 a.m. – 12:00 p.m. ET)
Poster Discussion Session Date & Time: Saturday, June 1, 2019 from 3:00 p.m. – 4:30 p.m. CT (4:00 p.m. – 5:30 p.m. ET)
Abstract Number: 11022
24th Congress of the European Hematology Association (EHA) (Free EHA Whitepaper)
June 13-16, 2019; Amsterdam, The Netherlands
Oral Presentation
Presentation Title: Avapritinib, a potent and selective inhibitor of KIT D816V, induces complete and durable responses in patients (pts) with advanced systemic mastocytosis (AdvSM)
Session Title: New Agents in MPN
Presentation Date & Time: Saturday, June 15, 2019 from 12:00 p.m. – 12:15 p.m. CEST (6:00 a.m. – 6:15 a.m. ET)
Abstract Number: S830
Investor Event and Webcast Information
Blueprint Medicines will host an investor event on Monday, June 3, 2019 beginning at 6:30 p.m. CT (7:30 p.m. ET) in Chicago to provide a portfolio update, including a review of updated clinical data from the ongoing ARROW trial of BLU-667 in patients with RET-altered cancers and the ongoing registration-enabling NAVIGATOR trial in patients with PDGFRA Exon 18 mutant and fourth-line GIST. The event will be webcast live and can be accessed under the "Investors & Media—Events & Presentations" section of Blueprint Medicines’ website at www.BlueprintMedicines.com. A replay of the webcast will be available approximately two hours after the event and will be available for 30 days following the event.